The “black box” warning on the popular diabetes and weight loss drug semaglutide may be shifting from a cautionary black to a reassuring grey. A landmark study published in The Journal of Clinical Endocrinology & Metabolism reveals that semaglutide does not promote thyroid cancer; instead, it may suppress tumor growth by “reprogramming” the immune system […]
New Research Challenges Fears of Semaglutide-Linked Thyroid Cancer Risk
Join the Global Movement Advancing Endocrine Science and Medicine
Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.